Stockholm, Sweden, 7-02-2023 – Life Science Newswire – NDA Group is proud to announce the appointment of Erik Bech-Jansen as the new Chief Financial Officer. Erik brings over 30 years of financial expertise and leadership to the company and will be responsible for leading NDA's financial strategy, planning and analysis, and accounting functions.

Erik has a proven track record of driving growth, improving operational efficiency, and developing innovative financial solutions to help organizations succeed. Erik also has extensive experience from corporate transactions as well as restructuring activities, adding a new set of capabilities to the Group.

NDA Group CEO Johan Strömquist said, "We are thrilled to welcome Erik to NDA. He brings a wealth of experience and expertise to our team and will play a critical role in driving our financial strategy and growth. We are confident that Erik will help us reach new heights and continue to deliver the highest quality services to our clients."

Erik added, "I am very excited to join NDA Group a company that provides unmatched regulatory expertise to their clients all around the world. I look forward to working with the talented team and contributing to the company's success, particularly at a time when the opportunities for accelerated growth are so many."

About NDA Group

NDA is a world-leading regulatory and drug development consultancy company, with 25 years of unparalleled expertise and an extensive portfolio of services through all phases of drug development.

Our dedicated team of over 150 consultants combined with the unique NDA Advisory Board provide drug developers with unmatched regulatory expertise, ensuring the safe development of complex & innovative treatments that meet the rigorous requirements of the regulatory agencies.

Over the last three years, NDA Group has supported a quarter of the new medicinal products approved in the US and Europe.

www.ndareg.com